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Abstract
Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and 
associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the 
notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of 
CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved 
survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper 
of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs 
will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, 
etelcalcetide, a drug available in Italy since few months ago.
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Introduction
Secondary hyperparathyroidism (SHPT) is a common, 
severe and costly complication of Chronic Kidney Disease 
(CKD), and it has an unfavorable impact on outcomes of 
patients, particularly in those undergoing hemodialysis [1–3] This manuscript is dedicated to the memory of our colleague 
Augusto Genderini, who suddenly passed away during the 
preparation of it.
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(please refer to Table 1 for a complete list of abbreviations 
and acronyms).
Although many treatment approaches are available, 
remarkable proportions of patients still present inappropriate 
serum levels of parathyroid hormone (PTH), phosphate and 
calcium, often reaching far beyond what is recommended 
by the guidelines for the treatment of Chronic Kidney Dis-
ease Mineral Bone Disorder (CKD-MBD) [1, 4–6]. In the 
COSMOS study [4], a review of approximately 4500 sub-
jects in 227 European dialysis centers, phosphate levels were 
higher than normal in 70% of dialysis patients, reaching val-
ues beyond 5.5 mg/dl in 41% of them. Similarly, only about 
one patient out of two (55.4%) in Italy present values of 
CKD-MBD parameters within the desired ranges [4]. In the 
US, based on the data from the Dialysis Outcomes Prac-
tice Patterns Study (DOPPS), a survey performed in 2015, 
phosphate levels were higher than recommended by the 
guidelines for CKD-MBD management in more than 60% 
of prevalent patients undergoing hemodialysis treatment 
longer than 180 days [6]. With regard to the plasma levels 
of PTH, according to DOPPS data, a progressive increase 
of median levels has been observed in the last years both in 
Europe and the US [5]. In the 2012–2014 timeframe of the 
survey, in particular, more than 25% of patients treated in 
the US presented with poorly controlled SHPT (defined as 
PTH level > 500 pg/ml) [5]. In line with these observations, 
hyperparathyroidism was reported in a recently published 
study in as much as 29% of patients receiving chronic hemo-
dialysis in Italy [7]. In addition to such an assessment of the 
grade of appropriateness in the management of SHPT both 
in Italy and internationally, DOPPS data show that, in dialy-
sis patients, there’s an increase in the risk of cardiovascular 
mortality and all-cause mortality associated with serum 
calcium levels > 10 mg/dl, phosphate levels > 7 mg/dl, and 
PTH levels > 600 pg/ml [8], so as to highlight how much 
an appropriate control of SHPT and CKD-MBD is still an 
unmet clinical need.
Current strategies for the medical treatment of SHPT are 
grounded in the following criteria: lower the intake of phos-
phate by careful avoiding food and beverages with “masked” 
phosphorus content (many preserved foods and alcohol-free 
beverages) [9, 10]; privilege the intake of proteins of vegetal 
origin which, due to higher content in fiber, cause lower 
intake of phosphorus so as to reduce animal proteins while 
avoiding malnutrition; use phosphate binders [10, 11]; use 
vitamin D analogs [7, 12, 13]; ensuring dialysis appropri-
ateness in dialysis patients, with particular regard to dura-
tion; use of calcimimetics (Table 2). The latter are chemical 
agents which activate calcium sensing receptor (CaSR) and 
suppress PTH secretion from the parathyroid glands [1–3]. 
Parathyroidectomy is usually the last resort treatment and 
is only performed after evidence of failure of drug therapy 
[1–3, 7, 14], and a careful evaluation of all potential com-
plications of such surgery procedure [15].
The goal of the treatment is to maintain calcium, phos-
phate and serum PTH below the levels advised by the guide-
lines for CKD-MBD management [2]. However, partly 
because of the limitations of the current therapeutic options 
for SHPT, a large proportion of patients on chronic replace-
ment therapy do not reach target levels of PTH [4–6]. It 
is not thus surprising that the research in this field is still 
ongoing with the aim of developing molecules able to offer 
new therapeutic solutions for clinicians to cure bone mineral 
disorders [3].
Table 1  List of abbreviations and acronyms used in the present paper and relevant explanations
Abbreviation Meaning
CAC Coronary artery calcification
CaSR Calcium sensing receptor
CKD Chronic kidney disease
CKD-G5D Chronic kidney disease under dialysis treatment
CKD-MBD Chronic kidney disease mineral bone disorder
COSMOS Observational clinical study in patients undergoing maintenance dialysis treatment in Europe
DOPPS Dialysis examinations and practice patterns study
EAP Efficacy assessment period
EVOLVE Evaluation of Cinacalcet HCl therapy to lower cardiovascular events trial
FGF23 Fibroblast growth factor 23
iPTH Intact Parathyroid hormone
KDIGO Kidney disease improving global outcomes (the Organization that issued the guidelines)
PTH Parathyroid hormone
SAPC Serum albumin peptide conjugate
SHPT Secondary hyperparathyroidism
VDR Vitamin D receptor
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In this “Position Paper”, we are going to present the 
updates of the guidelines for CKD-MBD management issued 
by Kidney Disease Improving Global Outcomes (KDIGO) 
and the evidence available on etelcalcetide, a novel calcimi-
metic agent administered intravenously, which a few months 
ago entered the therapeutic armamentarium of nephrologists 
who are struggling with the management of SHPT.
KDIGO guidelines on CKD‑MBD management: new 
updates
The updates of the guidelines for diagnosis, evaluation, pre-
vention and treatment of CKD-MBD in patients with chronic 
kidney disease were released in August 2017 [16] at the 
end of a long internal review process. In fact, the changes 
from previous 2009 guidelines are modest, particularly with 
regard to management and therapy of SHPT [16].
Among the new recommendations, the importance of 
serial assessments of phosphate, calcium, and PTH levels 
considered together, is reiterated under point 4.1.1 of the 
guidelines [16]. When deciding or modifying the treatment 
of CKD-MBD, it is indeed important to consider the set of 
these biochemical markers as a whole, and to also take into 
account their trends in time, an aspect that is often neglected 
by clinicians. In patients in dialysis (CKD-G5D) it is sug-
gested to maintain phosphate levels in the normal range, 
avoid hypercalcemia, and use a dialysate calcium concentra-
tion between 1.25 and 1.50 mmol/l (grade and strength of 
the recommendations: 2C) [16]. Concerning management 
and adjustment of PTH levels, the recommendation (under 
point 4.2.3, grade and strength 2C) is unchanged from year 
2009 [2, 16], i.e. it is suggested to maintain PTH levels in 
the range of 2–9 times the upper normal limit reported by 
the lab and, importantly, to initiate or change therapy in case 
of progressive changes in PTH levels, even if still within 
Table 2  Available marketed treatments for secondary hyperparathyroidism
a Available for patients on renal replacement therapy only
Treatment Formulation Starting dose Most common side effects
Phosphate binders
Calcium based
 Calcium  acetatea 667 mg capsules 667–1334 mg Nausea, vomiting, elevated serum 
calcium
 Calcium carbonate 250–1000 mg tablets 500–1000 mg Nausea, vomiting, elevated serum 
calcium, diarrhea, abdominal pain, 
flatulence, constipation
 Calcium acetate + magne-
sium carbonate
435 mg + 235 mg 180 film-coated 
tablets
3 to 10 film-coated tablets daily, 
depending on serum phosphate 
level
Nausea, loss of appetite, feeling of 
fullness, belching, constipation and 
diarrhea, loose stool, symptomatic 
or asymptomatic elevation of serum 
calcium, asymptomatic elevation of 
serum magnesium
Non calcium based 
 Sevelamer
HCl/carbonate
800 mg tablets, 2400 mg sachets 
(oral suspension powder)
800-1600 mg 3 times daily with 
meals
Headache, diarrhea, dyspeptic 
disorders
 Lanthanum carbonate 250, 500, 750, 1000 mg chewable 
tablets
1500 mg daily Diarrhea, nausea, abdominal pain, 
vomiting
 Sucroferric oxyhydroxide 500 mg chewable tablets 1500 mg of iron (3 tablets) daily Diarrhea, stool color change, nausea, 
vomiting, constipation
Active vitamin D analogs
Calcitriol 0.25 mcg capsules 0.25 mcg daily Elevated serum calcium, headache, 
abdominal pain, nausea, skin rash, 
urinary tract infections
1 mcg injectable solution 1.0 mcg (0.02 mcg/kg) to 2.0 mcg 3 
times weekly (every other day)
Paricalcitol 1, 2, 4 mcg capsules 1-2 mcg (PTH < 500 pg/ml) or 2-4 
mcg (PTH > 500 pg/ml) every 
other day
Diarrhea, arterial hypertension, dizzi-
ness, vomiting and elevated serum 
calcium
5 mg/ml vials
Calcimimetics
Cinacalcet 30, 60, 90 mg tablets 30 mg daily Reduced serum calcium, muscle 
spasms, diarrhea, nausea, vomiting
Etelcalcetide 2.5 mg, 5 mg, 10 mg vials 5 mg bolus injection 3 times weekly Reduced serum calcium, muscle 
spasms, diarrhea, nausea, vomiting
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the suggested range. This recommendation applies for either 
increased or decreased PTH levels, in order to avoid both 
hypercorrection and suboptimal treatment of SHPT [16]. As 
it is shown in Table 2, many drugs are available to improve 
SHPT, and guidelines suggest to use calcimimetics, calci-
triol, vitamin D analogs or a combination of these in patients 
in dialysis (point 4.2.4, 2B) [16]. The choice of the treatment 
and the assessment of the best therapeutic strategy are up to 
the physician in charge of the single patient, based on his/
her biochemical pattern, as it is reported under the above 
mentioned point 4.1.1 of the guidelines [2, 16].
Among the working group who reviewed the KDIGO 
2017 guidelines there was no consensus as to the indica-
tion for the use of calcimimetics as first line treatment in 
CKD-G5D and SHPT patients (Table 3). Several studies 
show superior efficacy of cinacalcet as compared to active 
vitamin D or its analogs for the simultaneous control of both 
PTH and the other bone mineral metabolism markers (serum 
calcium, serum phosphate, FGF23) [17–23]. Therefore, in 
our opinion calcimimetics should be seen as first line drugs 
to control SHPT in patients with moderately to severely ele-
vated serum calcium levels and elevated levels of phosphate, 
while active vitamin D or its analogs should be used as first 
choice in patients with hypocalcemia. However, it is neces-
sary to remind that in most cases the best control of SHPT 
is achieved in the later phase using a balanced combination 
of calcimimetics and low doses of active vitamin D or its 
analogs.
Indeed, several randomized clinical trials have proven 
that combined therapy with cinacalcet and low doses of 
active vitamin D might achieve better control of SHPT in 
comparison with solely using active analogs of vitamin D 
[17–23].
In a study by Urena et al. [18] conducted in 300 inci-
dent patients undergoing hemodialysis, combined therapy 
with cinacalcet and low doses of active vitamin D (aver-
age weekly dose of paricalcitol 4.5 mcg) achieved greater 
reduction of PTH levels, along with lower average levels of 
serum calcium and phosphate (8.7 vs. 9.3 mg/dl and 5.1 vs. 
5.5 mg/dl respectively) as compared with monotherapy with 
paricalcitol (average weekly dose 11.7 mcg).
In the IMPACT study [23], the control of PTH levels 
was similar between subjects treated with cinacalcet and 
low doses of vitamin D and those who were treated with 
monotherapy either with paricalcitol or analogs of vitamin 
D. However, in comparing study-end and baseline serum 
levels, a trend was observed toward a decrease in phosphate, 
calcium and FGF23 among patients treated with cinacalcet, 
while the same markers were increased by the use of intra-
venous or oral paricalcitol. Furthermore, in around 11% of 
patients treated with paricalcitol, hypercalcemia (defined as 
serum calcium over 11 mg/dl) was detected.
Also the PARADIGM study [20], conducted in 312 
dialysis patients, showed comparable control of PTH lev-
els between the group treated with cinacalcet (median daily 
dose at 52 weeks 85 mg) and the one treated with parical-
citol (median weekly dose at 52 weeks 21 mcg). However, 
serum calcium, phosphate and FGF23 were significantly 
reduced in patients treated with cinacalcet, while the same 
markers were increased in the paricalcitol group [20].
According to the “Evidence based medicine”, the 
EVOLVE study (Evaluation of Cinacalcet HCl Therapy to 
Lower Cardiovascular Events) [17], the largest placebo-con-
trolled double-blind clinical trial ever conducted in dialysis 
patients with SHPT, was not able to prove superiority of 
cinacalcet over placebo in achieving the more ambitious 
composite primary end-point of all-cause mortality, myo-
cardial infarction, unstable angina requiring hospitalization, 
heart failure or peripheral vascular disease [17]. The sta-
tistical inconclusive significance of the study is due to the 
reduction of its statistical power from 90% to 54% [24], as a 
consequence of both the decision of the physicians in charge 
to treat placebo patients with a calcimimetic, and the side-
effects drop-out rate from the calcimimetic drug, mainly due 
to gastrointestinal events.
Therefore, on the one hand clinical trials using surrogate 
endpoints like biochemical markers control have proven a 
specific pattern achieved by the calcimimetic; on the other, 
the EVOLVE study [17] could not prove an impact of CaSR 
modulation on hard endpoints. In fact, at the end of the 
64-month treatment period, the reduction of the composite 
risk of all-cause mortality, myocardial infarction, unstable 
angina requiring hospitalization, heart failure or peripheral 
vascular disease was proven non-significant (Hazard Ratio 
0.93; 95% Confidence Interval 0.85–1.02; p = 0.11) [17]. 
Nevertheless, in the EVOLVE study the risk of developing 
severe and unremitting hyperparathyroidism and undergo 
parathyroidectomy was shown to be lower in the cinacal-
cet group than in controls (who were treated with active 
vitamin D and/or phosphate binders) [25]. This observa-
tion, however, is based on secondary or post hoc analysis 
and it requires further evidence. Other interesting findings 
from the EVOLVE study are listed in Table 4 [26–30]. Treat-
ment with cinacalcet was more beneficial in individuals of 
age over 65 years as compared to the younger ones [29]. In 
general, the risk of calciphylaxis [30], non-atherosclerotic 
Table 3  Main messages arising from the latest KDIGO review of the 
guidelines on CKD-MBD management [16, 17]
KDIGO guidelines
 It is important to evaluate the set of biochemical markers as a whole 
and their trends in time
 Hypercalcemia should be avoided
 Calcimimetics are among first choice options to consider in stage-
5D CKD patients
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cardiovascular events [27], calcifications [28], and bone 
fractures [26] seemed to be lower when CKD-MBD therapy 
included the use of a CaSR modulator.
In summary, the current clinical evidence does not allow 
to draw clear indications on which therapy of SHPT should 
be chosen as first line, but it actually suggests that the treat-
ment strategy should be tailored to the biochemical pattern 
of each patient, leaving physicians free to make the clinical 
choices they deem appropriate for their patients. Clinical 
common sense tells us we should follow the suggestions 
here above.
When and how to start drug treatment of SHPT?
The KDIGO guidelines include only very general advices 
about when to initiate treatment with drugs able to reduce 
the levels of PTH. At point 4.2.3, among other things, the 
KDIGO guidelines [2, 16] suggest to start treatment when 
repeated increases of PTH levels are observed, even within 
the suggested range, in order to avoid progression of the 
condition of SHPT [2, 16].
In clinical practice, however, such suggestion does not 
seem to be much followed [5]. The latest DOPPS data show 
that SHPT treatment is generally started late, namely, when 
PTH has exceeded the recommended target [5, 6]. In contrast 
with the increase of the average levels of PTH observed dur-
ing the study period, prescription of active vitamin D was 
frequent (around 80% of patients were treated with vitamin 
D) but it remained stable. Changes were not seen either in 
the prescription of cinacalcet, that remained stable and lim-
ited to around 20% of white and 37% of black patients [5, 6]. 
Although cinacalcet use has been associated with parathy-
roid gland volume reduction even in patients with marked 
parathyroid hyperplasia [31], there are physiopathological 
and clinical considerations that should push to start treating 
SHPT as early as possible, with the aim of achieving optimal 
and simultaneous control of multiple mineral metabolism 
markers and slow and/or contain the progression of SHPT 
[1, 3]. In detail, it is thought that chronic and abnormal stim-
ulation of the parathyroid glands to release PTH might lead 
to structural changes of the glands themselves which, with 
time, become progressively less sensitive to mechanisms 
regulating PTH production and therefore also to medical 
therapy (unremitting SHPT) [32, 33]. Delaying treatment of 
SHPT might therefore mean to jeopardize its efficacy [32, 
33].
There are substantial differences, though, among classes 
of drugs able to control PTH. When deciding the treatment 
for CKD-MBD, it is important to take these differences into 
account. In particular, the effect of the administration of 
vitamin D on calcium and phosphate balance can be very 
different from that of a CaSR modulator [34–41]. We know 
that, in dialysis patients, serum levels of calcium and phos-
phate do not only depend on dietary intake and intestinal 
absorption but also on dialysis balance and bone resorption 
of these elements [40, 41]. Protein intake being equal, for 
example, the risk of hyperphosphatemia increases with PTH 
levels [42–44]. In detail, in patients with protein intake from 
Table 4  Key findings from the evalution of Cinacalcet HCL Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Summarized results include Hazard Ratios (HR) for the comparison between cinacalcet and placebo
Statistically significant results are in bold
a For a full presentation of the results of the EVOLVE trial please refer to Locatelli F, et al. What can we learn from a statistically inconclusive 
trial? Consensus conference on the EVOLVE study results. G Ital Nefrol 2013 Sep-Oct;30 [5]. pii: gin/30.5.4 [31]
Primary endpoint
Composite risk of all-cause mortality, myocardial infarction, unstable angina requiring hospitalization, 
heart failure or peripheral vascular disease (not adjusted for confounding factors)
HR 0.93; (95% CI 0.85–1.02) [11]
Secondary endpoints and post hoc analyses
Composite risk of all-cause mortality, myocardial infarction, unstable angina requiring hospitalization, 
heart failure or peripheral vascular disease (adjusted for confounding factors)
HR 0.88; (95% CI 0.79–0.98) [11]
Composite risk of all-cause mortality, myocardial infarction, unstable angina requiring hospitalization, 
heart failure or peripheral vascular disease (lag censoring)a
HR 0.85; (95% CI 0.76–0.95) [11]
Composite risk of all-cause mortality, myocardial infarction, unstable angina requiring hospitalization, 
heart failure or peripheral vascular disease in individuals older than 65 years of age
HR 0.70; (95% CI 0.60–0.81) [22]
Composite risk of all-cause mortality, myocardial infarction, unstable angina requiring hospitalization, 
heart failure or peripheral vascular disease in individuals younger than 65 years of age
HR 0.97; (95% CI 0.86–1.09) [22]
Risk of bone fractures, unadjusted HR 0.89; (95% CI 0.75–1.07) [19]
Risk of bone fractures, adjusted for potential confounding factors HR 0.83; (95% CI 0.72–0.98) [13]
Fatal and non-fatal non-atherosclerotic/ischemic cardiovascular events (e.g. arrhythmia) HR 0.84; (95% CI 0.74–0.96) [20]
Risk of parathyroidectomy or severe SHPT (unremitting) HR 0.31; (95% CI 0.26–0.37) [18]
Risk of calciphylaxis HR 0.31; (95% CI 0.13–0.79) [23]
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0.8 to 1.2 g/kg/day the risk of hyperphosphatemia increases 
significantly when levels of PTH are > 300 pg/ml (as com-
pared to the population with PTH levels from 150 to 300 pg/
ml) [43].
In another study conducted in more than 100,000 
patients undergoing maintenance dialysis treatment, the 
risk of hyperphosphatemia (defined as serum phosphate 
levels > 5.5 mg/dl), hypercalcemia (defined as serum cal-
cium levels > 10.2 mg/dl) and elevated alkaline phosphatase 
(> 120 U/L) increased progressively with PTH levels [44], 
thus showing an important role of bone turnover in deter-
mining serum levels of these elements [44].
As compared to active analogs of vitamin D, cinacalcet 
does not increase the intestinal absorption of phosphate and 
is effective in reducing elevated bone turnover [34–41]. The 
action on bone turnover might indeed explain the finding of 
serum levels of calcium and phosphate generally lower in 
patients treated with a CaSR modulator than in those treated 
with vitamin D or its analogs [34–41].
Based on the available evidence and the physiopathologi-
cal arguments discussed above, it seems reasonable to initi-
ate treatment before the condition of unremitting SHPT is 
reached, using one or more drugs enabling the control of 
multiple biochemical markers at the same time.
Calcimimetics: when and how to use these 
molecules? Suggestions from the working group
As it was discussed above, calcimimetics are a first line 
therapeutic option for the treatment of SHPT in patients 
with moderately to severely elevated serum calcium levels 
and elevated levels of phosphate, who are receiving renal 
replacement therapy [2, 39]. Drugs belonging to this class 
bind and allosterically activate CaSR (allosteric agonists) 
[2, 39]. So far cinacalcet has been the only drug in this class 
available for therapy. Since few months ago also etelcal-
cetide is available in Italy; as compared to cinacalcet, the 
new drug has a different administration route (intravenous) 
and a different mechanism of CaSR activation. Furthermore, 
other molecules are under clinical development or are ready 
to enter the market [2, 39].
Unlike vitamin D and its analogs, calcimimetics are 
effective in reducing PTH without increasing the intesti-
nal absorption of calcium and phosphate [34–41]. Clinical 
studies have shown that treatment of SHPT with cinacalcet 
significantly reduces circulating levels of PTH [45]. After 
26 weeks of treatment with cinacalcet or placebo, levels of 
iPTH ≤ 250 pg/ml were achieved in a remarkable proportion 
of patients treated with the drug (43%) as compared to pla-
cebo (5%) [45], and also better control of serum calcium and 
phosphate, in association with higher suppression of PTH, 
were observed [45]. Further studies have confirmed the effi-
cacy of PTH suppression with cinacalcet, in combination 
with vitamin D or vitamin D analogs, as compared to mono-
therapy with calcitriol [46].
In the ACHIEVE study, PTH levels were reduced by at 
least 30% from baseline in 68% of patients receiving cina-
calcet and only in 36% of patients receiving active vitamin 
D as monotherapy [47]. In another open-label 16-week 
study, 71% of patients treated with active vitamin D in 
combination with a low dose of cinacalcet reached levels 
of PTH ≤ 300 pg/ml as compared to 22% of patients treated 
with vitamin D only [48].
In all these studies mild to moderate hypocalcemia was 
common but easily manageable [49]. Hypocalcemia is a side 
effect attributed to CaSR modulation and likely to a reduc-
tion of bone calcium mobilization due to stricter control of 
PTH [49].
Lastly, the EVOLVE study has confirmed that achiev-
ing target levels is easier in CKD-MBD patients who are 
treated with cinacalcet than in the ones treated with placebo 
[17, 25]. As we already discussed, despite the primary end-
point of the study (all-cause mortality, myocardial infarction, 
unstable angina requiring hospitalization, heart failure or 
peripheral vascular disease) was not reached, serum levels 
of iPTH, calcium, phosphate and FGF-23 were better con-
trolled among patients assigned to the cinacalcet treatment 
group [19, 25]. As compared to the placebo group, the most 
common side effects related to treatment with calcimimetics 
were nausea, vomiting and hypocalcemia; the prevalence of 
hypocalcemia was 12% in the cinacalcet group and 2% in the 
placebo group [17]. These side effects likely contributed to 
the higher discontinuation rate due to adverse events (16% in 
the cinacalcet group versus 12% in the placebo group) [24].
Activation of CaSR can have beneficial effects through 
the control of serum biochemical markers [1, 22, 24, 36, 39, 
50]. Although inconclusive, the ADVANCE study, a phase 
4 randomized clinical trial [22], showed a trend towards 
slower progression of cardiovascular calcifications in sub-
jects treated with cinacalcet and low doses of active vitamin 
D, as compared to subjects treated with varying doses of 
vitamin D as monotherapy [22]. Following analyses showed 
that patients who were adherent to therapy or presented with 
large coronary and/or heart valve calcifications, seemed to 
benefit more greatly from this combined therapy [18]. In a 
post hoc analysis, subjects with aortic valve calcification 
treated with CaSR modulators showed a 74% reduction in 
the risk of progression of CAC (Odds Ratio 0.26; 95% CI 
0.10–0.64) [51]. Also in the ADVANCE study, the most 
common side effects reported by subjects assigned to treat-
ment with cinacalcet were gastrointestinal disorders and 
hypocalcemia, which occurred in 21% and 7%, respectively, 
of patients treated with this drug [22].
Although the activation of CaSR is an effective thera-
peutic strategy to control SHPT, further studies are needed 
to clarify the effect of potential interactions with various 
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drugs commonly used to control CKD-MBD. According 
to a recent post hoc analysis of the INDEPENDENT study 
data [35], the concomitant administration of cinacalcet 
and Sevelamer significantly modulated the impact of these 
drugs on mortality (p = 0.006): treatment with cinacalcet, 
with or without Sevelamer, yielded longer survival (Hazard 
Ratio 0.34, 95% CI 0.14–0.81, p = 0.01) than the combined 
treatment of cinacalcet and calcium-based phosphate bind-
ers (Hazard Ratio 1.28, 95% CI 0.82–2.00, p = 0.26) [35]. 
Although further verification is required, these data suggest 
that the activation of CaSR might modulate balance of cal-
cium [34] and affect survival of patients with CKD. Overall, 
however, the scientific evidence accumulated so far points to 
the need of a careful selection of the appropriate therapeutic 
strategy in SHPT.
CKD‑MBD, a field of intense research: new scenarios
On the date of January 26th 2018, 160 trials in SHPT were 
reported in the clinical trials register (www.clini caltr ials.
gov; keyword: secondary hyperparathyroidism); 143 were 
completed or early terminated, and 17 were actively ongo-
ing. Of these, 16 were interventional studies (four in phase 
1, one in phase 2, three in phase 3, three in phase 4, and five 
unclassified), and one was listed as an observational study. 
Such numbers show that treatments and interventions tar-
geting the mechanisms of development and progression of 
SHPT are a current area of interest.
Etelcalcetide (formerly denominated AMG 416) is a 
new prolonged-action drug, whose molecule is composed 
by a linear chain of seven amino acids, with the ability to 
activate CaSR (calcimimetic) [52–55]. Etelcalcetide binds 
directly to CaSR, inhibiting the production and secretion of 
PTH by parathyroid glands [52–55]. Such action is due to 
the formation of a disulfide bridge between d-cysteine in 
the etelcalcetide molecule and l-cysteine in CaSR, result-
ing in a fast activation of receptors [52–55]. Many scientific 
articles have been published in the last 2 years concerning 
pharmacokinetics, biotransformation and excretion of the 
drug both in animal models and in CKD patients undergo-
ing hemodialysis treatment [52–55]. A summary of the main 
characteristics of etelcalcetide compared with cinacalcet is 
reported in Table 5.
Biotransformation of circulating etelcalcetide mainly 
yields a covalent conjugate with serum albumin (SAPC) 
[52–56]. The process of biotransformation in the human 
bloodstream is reversible, but the rate of formation of SAPC 
from etelcalcetide is faster than the inverse process [52–56]. 
These properties account for reduced extrarenal elimination 
and longer blood half-life of the drug [52–56]. When etelcal-
cetide was intravenously administered to CKD patients 
under chronic replacement therapy, the drug predominant 
clearance route was the dialysis treatment itself. Around 60% 
of the dosage was indeed found in the dialysate [52–56]. 
Based on these considerations, etelcalcetide should be given 
after the dialysis session in order to avoid the elimination of 
a substantial fraction of the administered dose and achieve 
long duration of action of the drug [52–56]. Similarly, due 
to elimination of a substantial fraction of the administered 
etelcalcetide dose in the presence of a significant residual 
renal function, together with the route (intravenous) and 
frequency (three times per week) of administration make 
this drug not suitable for treating hyperparathyroidism in 
peritoneal dialysis patients.
The efficacy of etelcalcetide was tested in several clinical 
trials versus placebo or cinacalcet in patients with CKD-G5D 
Table 5  Summary of the differences in clinical and pharmacological properties between etelcalcetide (AMG 416) and cinacalcet
a In the study comparing the drugs, 52.4% of patients treated with etelcalcetide showed a reduction of at least 50% in PTH levels at the end of a 
26-week period of treatment vs. 40.2% of patients treated with cinacalcet (difference 10.2%, p = 0.001) [58]
Etelcalcetide Cinacalcet
Pharmacokinetics
 Composed by 8 synthetic amino acids (molecular weight 1048 g/mol) Small organic molecule
(molecular weight 393 g/mol)
 Interacts with the extracellular domain of CaSR and reduces PTH secretion Interacts with the intramembrane domain of 
CaSR and reduces PTH secretion
Long term action Short term action
Clinical use
 Intravenous administration Oral administration
 Three times weekly at the end of dialysis Daily use
 Better compliance Worse compliance
 Greater PTH suppression Lower PTH  suppressiona
 Higher incidence of asymptomatic hypocalcemia Lower incidence of asymptomatic hypocalcemia
 Similar incidence of gastrointestinal effects (nausea, vomiting, diarrhea) Similar incidence of gastrointestinal effects 
(nausea, vomiting, diarrhea)
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and SHPT [57–59]. In one of the first phase 2 dose-finding 
clinical trials [60], SHPT patients under hemodialysis treat-
ment were randomized by Bell and colleagues to one of 
three different study treatment regimens: etelcalcetide 5 mg 
or placebo for 2 weeks (cohort 1); etelcalcetide 10 mg or 
placebo for 4 weeks (cohort 2); and etelcalcetide 5 mg or 
placebo for 4 weeks (cohort 3) [60]. Mean percent change of 
PTH from baseline was statistically significant (p < 0.05) and 
dose-dependent [60], reaching − 49% and + 29% in subjects 
treated with etelcalcetide 10 mg and placebo, respectively, 
in cohort 2, and − 33% and + 2% for etelcalcetide 5 mg and 
placebo, respectively, in cohort 3 [60]. The proportions of 
patients who achieved a 30% reduction in PTH levels from 
baseline were 76% in the etelcalcetide 10 mg group versus 
10% in the placebo group (p < 0.0001). The proportion was 
lower in the etelcalcetide 5 mg group, equaling 54% ver-
sus 15% in the placebo group [60]. Finally, the numbers of 
patients achieving PTH levels below 300 pg/ml at the end 
of the study were 67% in the etelcalcetide 10 mg group and 
46% in the etelcalcetide 5 mg group [60].
A second study conducted in Japan confirmed these find-
ings even expanding them, as it suggested that the dose-
dependent reduction of PTH levels might be associated with 
a corresponding effect on markers of bone neo-formation 
(bone-specific alkaline phosphatase) and bone resorp-
tion (tartrate-resistant acid phosphatase 5b) [61]. In the 
two phase 3 studies versus placebo [59], etelcalcetide was 
given three times weekly to 508 patients with moderate to 
severe SHPT as compared to 515 patients who were given 
placebo. At the end of the 26-week study duration, active 
treatment significantly reduced the levels of PTH (75% ver-
sus 9% in the placebo group) and of FGF-23 (70% versus 
30% in the placebo group), and it also improved other bone 
mineral metabolism markers [59]. A post hoc analysis of 
the placebo-controlled study [62] evaluated the efficacy of 
etelcalcetide in achieving levels of PTH below 300 pg/ml 
according to specific baseline PTH levels. The results show 
that 69.2% of patients with baseline PTH < 600 pg/ml suc-
ceeded in achieving levels of PTH ≤ 300 pg/ml in the effi-
cacy evaluation period; such proportion is reduced to as low 
as 48,9% and 29,5% for patients with baseline PTH from 600 
to 1000 pg/ml and > 1000 pg/ml, respectively. These data are 
resulting from a symmetrical decrease of PTH levels com-
pared to baseline by 54.2%, 58.2% and 55.5% in the three 
categories of patients with baseline PTH < 600 pg/ml, from 
600 to 1000 pg/ml, and > 1000 pg/ml, respectively [62].
The phase 3 study recently published by Block and col-
leagues [58] showed that etelcalcetide was both non-inferior 
and superior to cinacalcet in controlling serum levels of 
PTH. A total of 683 patients from dialysis centers in Europe 
and the US were enrolled in this double-blind, double-
dummy study, of whom 340 were treated with intravenous 
etelcalcetide and 343 with oral cinacalcet [58]. At the end 
of the 26-week follow-up period, etelcalcetide was shown 
to be non-inferior to cinacalcet with regard to the propor-
tion of subjects whose PTH levels were reduced at least by 
30% from baseline (68.2% vs. 57.7% of patients treated with 
etelcalcetide and cinacalcet, respectively, non-inferiority p 
value < 0.001) [58] and superior to cinacalcet with regard to 
the proportion of patients whose PTH levels were reduced 
at least by 50% (52.4% vs. 40.2% of patients treated with 
etelcalcetide and cinacalcet, respectively, p = 0.001) [58]. It 
has to be noted that all patient subgroups in which the effi-
cacy of etelcalcetide was tested have shown the same effect 
of the new drug on PTH control [58]. A summary of key 
results from phase 3 studies is shown in Table 6.
The safety profile of etelcalcetide appears to be compa-
rable to the one reported for cinacalcet [57–60]. Adverse 
events reported during the treatment with etelcalcetide in 
clinical trials seem to be for the most part correlated to 
the mechanism of action of calcimimetic drugs. The most 
important risk for etelcalcetide is the induction of hypoc-
alcemia or events that might occur as a consequence of a 
decrease in serum calcium (for example, prolongation of 
QTc interval). The rate of these adverse events, in particular 
hypocalcemia or decrease of serum calcium to levels that are 
not considered as true hypocalcemia, is slightly higher than 
with cinacalcet. This is likely due to the higher potency of 
the new drug (Table 7).
During phase 2 and phase 3 clinical trials, a total of 
1655 subjects received at least one dose of etelcalcetide, 
and 499 of these received etelcalcetide for more than 
1 year [55, 57–59, 63]. In placebo-controlled trials, the 
most common adverse event was asymptomatic hypocal-
cemia (occurring in 63.8% of patients treated with etelcal-
cetide vs. 10.1% of patients treated with placebo). Based 
on Kaplan–Meier estimates, the median time to the onset 
of the first event of hypocalcemia is around 9.6 weeks 
[55, 57–59, 63]. The tolerability profile of etelcalcetide 
was basically comparable to that of cinacalcet. The most 
commonly reported adverse events were asymptomatic 
hypocalcemia and gastrointestinal disorders [58, 59]. In 
particular, asymptomatic hypocalcemia was reported in 
68.9% of patients treated with etelcalcetide and in 59.8% 
Table 6  Summary of key results from phase 3 studies on etelcalcetide
Etelcalcetide
 69% of patients with PTH < 600 pg/ml reached target < 300 pg/ml
 Etelcalcetide reduces PTH, calcium and phosphate
 Etelcalcetide showed superiority vs. cinacalcet with regard to the 
proportion of patients with > 30% and > 50% reduction of mean 
PTH from baseline during the EAP
 Decreased serum calcium was mild to moderate, transient and rarely 
caused the discontinuation of the drug  (Parsabiv® European Public 
Assessment Report. EMA/664198/2016. September 2016)
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of those who were treated with cinacalcet. In both trials, 
hypocalcemia was controlled by administration of larger 
doses of calcium salts or vitamin D supplements and/or 
etelcalcetide dose reduction or interruption. While there 
is not consensus, it is plausible that lower levels of serum 
calcium in absence of symptoms can be tolerated. On the 
other hand, calcimimetic rather than calcium or vitamin D 
dose adjustment may be the best course of action in case 
of symptomatic hypocalcemia [35]. Gastrointestinal events 
(diarrhea, nausea and vomiting) were reported in 46.7% 
of patients treated with cinacalcet and 37.8% of patients 
treated with etelcalcetide (Table 6) [58, 59]. Although 
intravenous administration bypasses the gastrointestinal 
tract, etelcalcetide only partially reduced gastrointestinal 
adverse events (nausea and diarrhea) (Table 6) observed 
with the use of cinacalcet. These effects are likely due to 
the systemic activation of CaSR, rather than at the level 
of the gastrointestinal mucosa [64]. Nevertheless, these 
symptoms are generally mild in severity and improve with 
etelcalcetide dose reduction or drug interruption.
In placebo-controlled clinical trials, prolongation of QT 
interval (500 ms) secondary to hypocalcemia was observed 
in 4.8% of patients treated with etelcalcetide and 1.9% of 
subjects on placebo. Close monitoring of calcium levels is 
thus needed in patients with risk factors like congenital long 
QT syndrome, previous history of QT prolongation, familial 
anamnesis of long QT syndrome, sudden cardiac death and 
other medical conditions (data from European Medicines 
Agency (EMA): Parsabiv summary of product characteris-
tics. Available from: http://www.ema.europ a.eu, accessed 
November 30, 2016) or dugs (metoclopramide, antibiotics, 
etc.) that can predispose to QT interval prolongation. Also, 
caution should be exerted in the context of potential drug-
to-drug interactions that can displace etelcalcetide from 
albumin binding and potentially worsen hypocalcemia or 
hypoglycemia when etelcalcetide is administered in diabetic 
patients with SHPT.
In dialysis patients, who undergo dialysis sessions three 
times weekly, regular monitoring of electrolytes and CKD-
MBD biochemical markers seems sufficient to prevent the 
occurrence of severe adverse events. In this regard, the open 
label one-year extension of the three previously described 
phase 3 studies further corroborates the risk-to-benefit pro-
file of etelcalcetide, without raising any additional safety 
concerns associated with longer-term exposure to the drug 
[62].
Etelcalcetide was associated with greater-than-placebo 
reductions in bone mineral metabolism markers (bone alka-
line phosphatase and type 1 collagen C-terminal telopeptide) 
and fibroblast growth factor 23 (exploratory endpoints) at 
the end of the study (week 27) in placebo-controlled regis-
tration trials as well [59].
Closing remarks
Pharmacological treatment of SHPT has made progress in 
the last years. The introduction of targeted therapies like 
VDR and CaSR selective modulators is offering more 
chances for an appropriate control of serum PTH levels, in 
particular in patients with CKD undergoing dialysis treat-
ment. Emerging intravenous therapies for SHPT like etelcal-
cetide (AMG 416) might improve patients’ therapeutic com-
pliance, reduce the number of drugs to take orally at home so 
as to simplify dosing schedules, and increase the likelihood 
to reach treatment goals suggested by the guidelines for the 
management of CKD-MBD (Table 2).
The question remains unanswered whether emerg-
ing SHPT treatments will prove they can reduce the risk 
of cardiovascular morbidity and mortality in CKD-G5D. 
Table 7  Incidence (%) of the 
most common drug-related 
adverse events
a Hypocalcemia defined as serum calcium levels adjusted for albumin < 8.3 mg/dl
More frequent adverse event Clinical trials versus placebo [59] Clinical trials versus cinacalcet 
[58]
Placebo 
(N = 513)
Etelcalcetide 
(N = 503)
Cinacalcet 
(N = 341)
Etelcal-
cetide 
(N = 338)
Diarrhea 8.6 10.7 10.3 6.2
Nausea 6.2 10.7 22.6 18.3
Vomiting 5.1 8.9 13.8 13.3
Decreased serum calcium 10.1 63.8 59.8 68.9
Hypocalcemiaa 0.2 7.0 2.3 5.0
Hypokalemia 3.1 4.4 5.3 3.8
Muscle spasms 6.6 11.5 5.9 6.5
Paresthesia 1.2 6.2 2.6 3.3
Arterial hypotension – – 2.9 6.8
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Emerging therapies seem effective in reducing PTH, restor-
ing mineral homeostasis, improving therapeutic compli-
ance, and they might help create prerequisite conditions 
to improve long-term outcomes in dialysis patients with 
SHPT. However, the final answer to such a question can 
only come from randomized clinical trials on the new drugs, 
like etelcalcetide.
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